KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, ...

Review the current KalVista Pharmaceuticals Inc (KALV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if KALV is the best investment for you.

Get the annual and quarterly balance sheet of KalVista Pharmaceuticals, Inc. (KALV) including details of assets, liabilities and shareholders' equity.

Here are some of the largest recent moves: BOXER CAPITAL MANAGEMENT, LLC removed 1,590,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $18,348,600; SILVERARC CAPITAL ...

KalVista Pharmaceuticals, Inc. (KALV) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency ...

KALV Stock Performance. Year to date, KalVista’s shares have surged 89% compared with the industry’s 5% growth. While commercial execution remains key, ...